Casentini Leopoldo, Fornezza Umberto, Perini Zeno, Perissinotto Egle, Colombo Federico
Center of Stereotactic Radiosurgery, S. Bortolo City Hospital, Vicenza; and.
J Neurosurg. 2015 Apr;122(4):818-24. doi: 10.3171/2014.11.JNS131552. Epub 2015 Jan 16.
Microsurgery is not the only option for larger vestibular schwannomas (VSs); recent reviews have confirmed the feasibility and efficacy of radiosurgery for larger VSs. This study illustrates the outcomes of a series of large VSs after multisession stereotactic radiosurgery (SRS).
A series of 33 VSs larger than 8 cm(3) (range 8-24 cm(3), mean 11 cm(3), median 9.4 cm(3)) were treated using the CyberKnife from 2003 to 2011 with the multisession SRS technique in 2-5 fractions (14-19.5 Gy). Five patients had undergone surgical removal and 5 had ventriculoperitoneal shunts. Nine patients were eligible for but refused surgery. Twelve patients were older than 70 years and 5 were younger than 40 years. Two female patients had neurofibromatosis.
The follow-up period ranged from 12 to 111 months (median 48 months); radiological growth control was achieved in 94% of cases: 19 tumors (58%) displayed no size variation or reduction in tumor diameter; 12 (36%), after a transient enlargement, presented with arrested growth or shrinkage. Seven patients had a volume reduction of more than 50%. Two patients (6%) needed debulking and 2 were treated with ventriculoperitoneal shunts. Actuarial progressionfree survival rates at 1 year and 5 years were 97% and 83%, respectively. Hearing was retained in 7 of the 8 patients with serviceable baseline hearing. Adverse events were limited to 1 case each of vertigo, tongue paresthesia, and trigeminal neuralgia.
The good control rate obtained with multisession SRS deepens the controversy of the radiobiology of VSs and may extend the indication of radiation therapy (fractionated or SRS) for large VSs to include patients without symptoms of mass effect. The limited number of cases and short follow-up period do not provide sufficient support for widespread application of multisession SRS in young patients. Further studies with multisession SRS are warranted.
显微手术并非大型前庭神经鞘瘤(VS)的唯一选择;近期综述已证实放射外科治疗大型VS的可行性和有效性。本研究阐述了一系列大型VS在多疗程立体定向放射外科治疗(SRS)后的结果。
2003年至2011年,使用射波刀采用多疗程SRS技术对33例体积大于8 cm³(范围8 - 24 cm³,平均11 cm³,中位数9.4 cm³)的VS进行治疗,分2 - 5次分割(14 - 19.5 Gy)。5例患者曾接受手术切除,5例进行了脑室腹腔分流术。9例患者符合手术条件但拒绝手术。12例患者年龄大于70岁,5例患者年龄小于40岁。2例女性患者患有神经纤维瘤病。
随访期为12至111个月(中位数48个月);94%的病例实现了放射学生长控制:19个肿瘤(58%)肿瘤大小无变化或肿瘤直径缩小;12个肿瘤(36%)在短暂增大后生长停滞或缩小。7例患者肿瘤体积缩小超过50%。2例患者(6%)需要减瘤,2例接受了脑室腹腔分流术治疗。1年和5年的无进展生存率分别为97%和83%。8例基线听力尚可的患者中有7例听力得以保留。不良事件仅限于1例眩晕、1例舌感觉异常和1例三叉神经痛。
多疗程SRS获得的良好控制率加深了VS放射生物学的争议,并可能将大型VS放射治疗(分次或SRS)的适应证扩大到无占位效应症状的患者。病例数量有限和随访期较短,不足以支持多疗程SRS在年轻患者中的广泛应用。有必要对多疗程SRS进行进一步研究。